Calamos Wealth Management LLC Sells 4,322 Shares of Astrazeneca Plc $AZN

Posted by George Bondi on Jul 14th, 2026

Calamos Wealth Management LLC lowered its holdings in shares of Astrazeneca Plc (NYSE:AZN – Free Report) by 13.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 27,227 shares of the company’s stock after selling 4,322 shares during the period. Calamos Wealth Management LLC’s holdings in Astrazeneca were worth $5,370,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Triumph Capital Management acquired a new position in Astrazeneca in the third quarter valued at approximately $25,000. MV Capital Management Inc. bought a new stake in shares of Astrazeneca in the 4th quarter valued at $26,000. Mascoma Wealth Management LLC acquired a new position in shares of Astrazeneca during the 1st quarter valued at $26,000. Bangor Savings Bank lifted its position in shares of Astrazeneca by 102.7% during the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after acquiring an additional 154 shares during the period. Finally, Eagle Bay Advisors LLC bought a new position in Astrazeneca during the fourth quarter worth $30,000. 20.35% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on AZN shares. DZ Bank upgraded shares of Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. The Goldman Sachs Group reiterated a “buy” rating on shares of Astrazeneca in a report on Wednesday, July 1st. UBS Group restated a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. HSBC lowered Astrazeneca from a “buy” rating to a “hold” rating in a research report on Monday. Finally, TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $211.00.

Read Our Latest Report on AZN

Astrazeneca Stock Performance

Shares of AZN stock opened at $169.79 on Tuesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. The firm has a 50-day moving average of $183.38 and a 200-day moving average of $188.67. Astrazeneca Plc has a one year low of $137.23 and a one year high of $212.71. The company has a market cap of $263.32 billion, a P/E ratio of 25.49, a P/E/G ratio of 1.39 and a beta of 0.24.

Astrazeneca (NYSE:AZN – Get Free Report) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The business had revenue of $15.29 billion for the quarter, compared to analysts’ expectations of $14.93 billion. Equities research analysts forecast that Astrazeneca Plc will post 10.28 EPS for the current fiscal year.

More Astrazeneca News

Here are the key news stories impacting Astrazeneca this week:

Positive Sentiment: AstraZeneca struck an exclusive global license deal for the lung-cancer drug Zegfrovy, a move that could strengthen its oncology pipeline and long-term growth prospects. Article Title
Positive Sentiment: UBS reiterated a Buy rating ahead of second-quarter results, saying AstraZeneca should deliver solid earnings and revenue. Article Title
Neutral Sentiment: Analysts from both the U.S. and U.K. cited a mixed setup, with some optimism on near-term results but limited scope for AstraZeneca to raise full-year guidance. Article Title
Negative Sentiment: HSBC downgraded AstraZeneca to Hold and cut its price target after the Wainua Phase 3 failure, saying the setback weakens the stock’s bull case. Article Title

Astrazeneca Company Profile

(Free Report)

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.